dc.contributor.author | Mohebali, Donya | en_US |
dc.contributor.author | Matos, Jason | en_US |
dc.contributor.author | Chang, James Ducksoon | en_US |
dc.date.accessioned | 2017-03-28T23:47:50Z | |
dc.date.issued | 2016 | en_US |
dc.identifier.citation | Mohebali, Donya, Jason Matos, and James Ducksoon Chang. 2016. “Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity.” Esc Heart Failure 4 (1): 71-74. doi:10.1002/ehf2.12113. http://dx.doi.org/10.1002/ehf2.12113. | en |
dc.identifier.issn | | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731630 | |
dc.description.abstract | Abstract Gemcitabine is a commonly used antineoplastic agent used to treat a variety of cancers with rarely reported cardiac side effects. We describe a case of a 67‐year‐old woman with follicular lymphoma who experienced a rarely reported side effect of gemcitabine: cardiomyopathy. This case highlights a multiple hit mechanism of myocyte damage that may occur following the use of multiple cardio‐toxic agents despite their administration in doses not associated with cardiotoxicity. | en |
dc.language.iso | en_US | en |
dc.publisher | John Wiley and Sons Inc. | en |
dc.relation.isversionof | doi:10.1002/ehf2.12113 | en |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292629/pdf/ | en |
dash.license | LAA | en_US |
dc.subject | Case Report | en |
dc.subject | Cardiomyopathy | en |
dc.subject | Cardio‐oncology | en |
dc.subject | Chemotherapy | en |
dc.title | Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity | en |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en |
dc.relation.journal | Esc Heart Failure | en |
dash.depositing.author | Mohebali, Donya | en_US |
dc.date.available | 2017-03-28T23:47:50Z | |
dc.identifier.doi | 10.1002/ehf2.12113 | * |
dash.contributor.affiliated | Mohebali, Donya | |
dash.contributor.affiliated | Matos, Jason | |